Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Robert Durant

Psychiatry Mount Pleasant, SC Medical Doctor

NPI 1932399292 CMS profile 360890

913 Bowman Rd Ste 104, Mount Pleasant, SC 29464

Open in the dashboard

General payments

$11,831

666 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Robert Durant of Mount Pleasant, SC is reported in the CMS Open Payments database as having received $11,831 across 666 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,950 101
2024 General $2,210 124
2023 General $2,037 112
2022 General $2,220 140
2021 General $1,433 76
2020 General $1,053 47
2019 General $929 66

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Robert Durant
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Robert Durant were reported at $1,950. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Robert Durant Psychiatry median Middle half National median
2019 $929 $184 $59–$605 $163
2020 $1,053 $119 $36–$372 $114
2021 $1,433 $143 $43–$576 $132
2022 $2,220 $153 $50–$590 $149
2023 $2,037 $170 $56–$651 $160
2024 $2,210 $179 $57–$673 $164
2025 $1,950 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $1,258 104 payments
  2. Otsuka America Pharmaceutical, Inc. $1,092 63 payments
  3. Corium, Inc. $1,014 58 payments
  4. Takeda Pharmaceuticals U.S.A., Inc. $1,001 39 payments
  5. Axsome Therapeutics, Inc. $911 37 payments
  6. Supernus Pharmaceuticals, Inc. $842 44 payments
  7. Ironshore Pharmaceuticals Inc. $707 29 payments
  8. Neos Therapeutics, LP $642 50 payments
  9. Janssen Pharmaceuticals, Inc $582 30 payments
  10. Sunovion Pharmaceuticals Inc. $567 27 payments
  11. Other $3,215 185 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $11,820 664 payments
  2. Education $11 2 payments
Products named General payments · program years 2019–2025
  1. REXULTI Psychiatry $1,023 59 payments
  2. Azstarys $1,014 58 payments
  3. TRINTELLIX $961 37 payments
  4. VRAYLAR $957 85 payments
  5. Auvelity $911 37 payments
  6. JORNAY PM $600 23 payments
  7. LATUDA $567 27 payments
  8. SPRAVATO $556 28 payments
  9. QELBREE $551 29 payments
  10. REXULTI Psychiatry $450 24 payments
  11. Other $5,115 312 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 16 drugs

Part D claims

420

Median for Psychiatry: 574

Drug cost

$16,759

Median for Psychiatry: $27,624

Branded share of claims

20.2%

Median for Psychiatry: 17%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Lurasidone Hcl Generic 14 $11,173
Venlafaxine Hcl Er Venlafaxine Hcl Brand 33 $910
Trazodone Hcl Generic 37 $779
Quetiapine Fumarate Generic 26 $690
Sertraline Hcl Generic 24 $598
Dextroamphetamine-Amphetamine Dextroamphetamine/Amphetamine Brand 17 $582
Lamotrigine Generic 38 $380
Gabapentin Generic 26 $345
Bupropion Xl Bupropion Hcl Brand 22 $283
Alprazolam Generic 52 $250

The 10 drugs with the highest cost, of 16 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 20,488 Part D prescribers listed as Psychiatry; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 24 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Azstarys
$343 — —
REXULTI
$311 — —
Auvelity
$263 — —
VRAYLAR
$239 — —
Adzenys XR-ODT
$140 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 24 in the dashboard with a free account

Records

666 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in South Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record